Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH2 | P48735 | 1/20 | 0.38 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.37 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | AKT1 | P31749 | 8/20 | 0.35 |
| ▸ | AKT2 | P31751 | 8/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.34 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.34 |
| ▸ | PLK1 | P53350 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3264547 | 0.93 | IDH2 (0.37) | IDH2SYKMAPTLMNAMAPK1 | |
| SCHEMBL3234022 | 0.78 | SYK (0.42) | IDH2AKR1C1SYKMAPTLMNA | |
| Dimethylamine SCHEMBL3266676 | 0.77 | SYK (0.40) | IDH2AKR1C1SYKMAPTLMNA | |
| SCHEMBL3264006 | 0.77 | SYK (0.42) | IDH2AKR1C1SYKMAPTLMNA | |
| SCHEMBL2269303 | 0.75 | BRD4 (0.39) | AKR1C1SYK | |
| SCHEMBL3233798 | 0.74 | VCP (0.43) | IDH2AKR1C1SYKMAPTLMNA | |
| SCHEMBL3265292 | 0.74 | SYK (0.43) | IDH2SYKMAPTLMNANPC1 | |
| SCHEMBL3262310 | 0.74 | ABCG2 (0.43) | IDH2AKR1C1NPC1RAB9AADORA1 | |
| SCHEMBL3229406 | 0.73 | CA12 (0.36) | IDH2AKR1C1SYKNPC1RAB9A | |
| SCHEMBL3236168 | 0.72 | AKT1 (0.40) | IDH2SYKMAPTLMNAAKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144722-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS GATA MODULATORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-06-10 | — | — | US | claimed |
| WO-2010028179-A1 | HETEROCYCLIC COMPOUNDS AS GATA MODULATORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-03-11 | — | — | WO | claimed |
| US-20100144722-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS GATA MODULATORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-06-10 | — | — | US | disclosed |
| US-20100144722-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS GATA MODULATORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-06-10 | — | — | US | disclosed |
| US-20100144722-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS GATA MODULATORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-06-10 | — | — | US | disclosed |
| WO-2010028179-A1 | HETEROCYCLIC COMPOUNDS AS GATA MODULATORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-03-11 | — | — | WO | disclosed |
| WO-2010028179-A1 | HETEROCYCLIC COMPOUNDS AS GATA MODULATORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144722-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS GATA MODULATORS | GATAD2B, GATAD2A, RUNX1 | IDH2 2386/4885AKR1C1 3588/4885SYK 571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.